Has Mitchell Weinberg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $144,597 in general payments to Mitchell Weinberg, MD across 339 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mitchell Weinberg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mitchell Weinberg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mitchell Weinberg, MD

Interventional Cardiology · Manhasset, NYNPI 1245498385

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $92,338 of the $144,597 with a category attached, or 63.9%. Boston Scientific accounts for 79.6% of it on its own, with 24 other manufacturers making up the rest. Among interventional cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$144,597in general payments, 2019–2025

Across 339 payments — averaging $426.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$115K
Medtronic$12K
Neptune Medical Inc.$5K
Johnson & Johnson$4K
Endologix LLC$2K
Cardiovascular Systems Inc.$1K
plus $5K from 19 others

$634,703in research payments, 2019–2025

Across 265 payments — averaging $2395.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Inari Medical, Inc.$266K
Boston Scientific$146K
Abbott$85K
Medtronic$74K
Microvention, Inc.$60K
Stryker$3K

What the payments were for

Consulting fees$92,33864%
Speaking & faculty fees$23,35016%
Grants$270%
Travel & lodging$8,7466%
Food & beverage$20,13514%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	156	$115,057
Medtronic(2 entities)	76	$12,435
Neptune Medical Inc.	1	$5,188
Johnson & Johnson	3	$4,161
Endologix LLC	5	$1,578
Cardiovascular Systems Inc.	38	$1,339
Abbott	19	$1,193
Philips North America LLC	6	$611
Siemens Medical Solutions USA, Inc.	4	$487
Microvention, Inc.	1	$400
Cook Medical LLC	6	$264
Bolton Medical Inc	3	$256
Shockwave Medical, Inc	4	$250
Terumo Medical Corporation	1	$250
Abiomed	3	$171
Penumbra, Inc.	2	$162
Edwards Lifesciences	2	$154
Sirtex Medical Inc	1	$134
AstraZeneca	1	$132
Acist Medical Systems, Inc.	1	$124
W. L. Gore & Associates, Inc.	1	$100
Cordis US CORP.	1	$62
Novartis	2	$42
Inari Medical, Inc.	1	$28
Bayer	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GENERAL - THERAPIES$31,889
GENERAL VASCULAR INTERVENTION$16,585
EKOSONIC$13,466
CLINICAL TRIAL PRODUCT$9,750
IN.PACT Admiral$5,144
XARELTO$4,161
JETSTREAM SC$2,478
COREVALVE EVOLUT R$1,614
ELUVIA$1,389
ENDOCROSS Device$1,365
Torus Stent Graft System$1,365
Resolute$1,105
CoreValve Evolut$927
HawkOne$481
RESOLUTE ONYX$452
AVVIGO Guidance System$441
ONYX FRONTIER$382
Diamondback Coronary$358
Peripheral Orbital Atherectomy System$358
Coronary Orbital Atherectomy System$358

How this compares

$144,597 in reported general payments places this provider in the 90th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York →

Medicare billing

Part B allowed, 2024

$126,443

Medicare patients

218

Services billed

772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ClopidogrelClopidogrel Bisulfate	19	$239
Atorvastatin Calcium	26	$238
Rosuvastatin Calcium	24	$103

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Manhasset

Michael KimManhasset$136K
Perwaiz MerajManhasset$74K
Sahil ParikhNew York$1.6M
Deepak BhattNew York$1.6M
Martin LeonNew York$1.5M
Evan ShlofmitzRoslyn$951K
Mohamed Azeem LatibBronx$816K
Yili HuangElmhurst$699K
Ali HaiderAstoria$492K
Sripal BangaloreNew York$482K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →